Hyaluronic Acid Filler CPM-V ± Lidocaine for Chin Augmentation: A Randomized, Multicenter, Open-Label Post-Market Follow-Up Study

Background: Volume Lidocaine (CPM-V+) for chin augmentation in a real-world setting. Methods: This prospective, open-label, randomized study was carried out in Germany. Participants seeking chin augmentation received treatment with CPM-V (n=58) or CPM-V+ (n=63), with an optional touch-up 4 weeks after. The primary effectiveness endpoint was change in chin volume (mL) from baseline to 12 weeks after the last injection (Week 12 or Week 16 for participants with touch-up treatment), measured by validated 3D facial imaging. Secondary endpoints included the change from baseline in the glabella-subnasale-pogonion (G-Sn-Pg) angle (°), the investigator- and participant-assessed Global Aesthetic Improvement Scales (iGAIS/pGAIS) scores, the investigator-assessed Merz Aesthetics Scale (MAS) for chin projection, and participant satisfaction with treatment evaluated by FACE-Q - Satisfaction with Chin. Safety was assessed through adverse event reporting. Results: From baseline to Week 12/16, chin volume increased by a mean (standard deviation [SD]) of 2.5 (0.2) mL (95% confidence interval 2.1, 2.9; p<0.0001) and mean (SD) G-Sn-Pg angle increased by 1.9° (1.7°). At Week 12/16, almost all participants experienced ≥1 point improvements from baseline in MAS for chin projection (91.4%), iGAIS (100%), and pGAIS (99.1%). The mean (SD) Rasch-transformed score FACE-Q - Satisfaction with Chin was 66.6 (18.7) at Week 12/16. Thirty participants (24.8%) reported treatment-related adverse events; incidence was similar between treatment groups and the majority of events were mild to moderate in intensity and transient in nature. Conclusion: CPM-V and CPM-V+ were effective for chin augmentation in aesthetic clinical practice. No new safety concerns were identified.